Showing results (11-20 of 7,567) with videos related to
Sort By:
Pageof 757
BMC Bioinformatics|October 18, 2017
chngpt: threshold regression model estimation and inferenceYouyi Fong, Ying Huang, Peter B Gilbert, et al.Journal of Causal Inference|January 2, 2016
Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice DefinitionPeter B Gilbert, Erin E Gabriel, Ying Huang, et al.Statistics in Medicine|April 27, 2010
Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or conceptsPeter B GilbertStatistical Communications in Infectious Diseases|December 14, 2020
Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial DesignsPeter B GilbertThe Journal of Infectious Diseases|June 26, 2021
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy TrialsYing Huang, Brian D Williamson, Zoe Moodie, et al.Vaccine|March 8, 2024
Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trialPeter B Gilbert, Youyi Fong, Nima S Hejazi, et al.Statistical Communications in Infectious Diseases|December 15, 2010
Increasing the Efficiency of Prevention Trials by Incorporating Baseline CovariatesMin Zhang, Peter B GilbertLifetime Data Analysis|October 30, 2015
Mark-specific hazard ratio model with missing multivariate marksMichal Juraska, Peter B GilbertJournal of the Royal Statistical Society. Series C, Applied Statistics|February 3, 2015
Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trialsPeter B Gilbert, Yanqing SunBiometrics|December 24, 2002
Flexible weighted log-rank tests optimal for detecting early and/or late survival differencesLang Wu, Peter B GilbertPageof 757